(19)
(11) EP 4 823 568 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24829130.4

(22) Date of filing: 16.12.2024
(51) International Patent Classification (IPC): 
A61K 31/41(2006.01)
A61K 31/513(2006.01)
A61K 31/7068(2006.01)
A61P 35/00(2006.01)
A61K 31/4745(2006.01)
A61K 31/519(2006.01)
A61K 45/06(2006.01)
A61P 35/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4745; A61K 31/513; A61K 31/519; A61K 31/41; A61K 31/7068; A61K 45/06; A61P 35/04; A61P 35/00
 
C-Sets:
  1. A61K 31/7068, A61K 2300/00;
  2. A61K 31/4745, A61K 2300/00;
  3. A61K 31/513, A61K 2300/00;
  4. A61K 31/519, A61K 2300/00;
  5. A61K 31/41, A61K 2300/00;

(86) International application number:
PCT/EP2024/086541
(87) International publication number:
WO 2025/125679 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 15.12.2023 EP 23217192
31.01.2024 EP 24155017

(71) Applicant: Resistance Oncology ApS
1256 København K (DK)

(72) Inventors:
  • STENVANG, Jan
    2100 Copenhagen Ø (DK)
  • ZURLO, Alfredo
    2100 Copenhagen Ø (DK)
  • ROEST, Nicklas Lindland
    2100 Copenhagen Ø (DK)

(74) Representative: IPTector Consulting ApS 
Diplomvej 377
2800 Kgs. Lyngby
2800 Kgs. Lyngby (DK)

   


(54) IMPROVED ANTI-CANCER TREATMENT REGIMEN